Pharmacokinetics and Safety of Long‐Acting Testosterone Undecanoate Injections in Hypogonadal Men: An 84‐Week Phase III Clinical Trial
Authors:
- 10 September 2010
- journal article
- research article
- Published by Wiley in Journal of Andrology
- Vol. 31 (5) , 457-465
Abstract
Currently available testosterone (T) injections in the United States are administered at 2–3 weekly intervals. Less frequent injections with favorable serum T pharmacokinetics would benefit hypogonadal men. The objective of this study is to assess the pharmacokinetics of long‐acting testosterone undecanoate (TU) intramuscular (IM) injection in hypogonadal men. An unblinded, multicenter phase 3 clinical trial was conducted in 31 academic centers and contract research organizations. Males (130) more than 18 years of age with serum total T < 300 ng/dL were enrolled and received 750‐mg injections of TU at weeks 0 and 4 and every 10 weeks thereafter for 9 injections over 84 weeks. The main outcome variables were serum total T, free T, dihydrotestosterone (DHT), estradiol (E2) levels, and safety parameters. After the first injection, patients maintained average trough T concentrations in the adult male range (300–1000 ng/dL or 10.4–34.7 nmol/L) before each injection and at multiple time points measured after the third and fourth injections. Serum free T, DHT, and E2 levels and their ratios to serum T remained relatively consistent once steady state was attained. TU injections were generally well tolerated, with safety profiles similar to other T replacement. We conclude that hypogonadal patients treated for 84 weeks with a 750‐mg IM injection of TU every 10 weeks demonstrated average concentrations of T, its metabolites (DHT and E2), and ratios—DHT:T and E2: T—within the adult male reference range at all time points measured. TU injections would be an acceptable alternative to the currently available 2–3 weekly injectables.Keywords
This publication has 25 references indexed in Scilit:
- Long Acting Testosterone Undecanoate Therapy in Men With Hypogonadism: Results of a Pharmacokinetic Clinical StudyJournal of Urology, 2008
- The effect of food composition on serum testosterone levels after oral administration of Andriol® Testocaps®Clinical Endocrinology, 2007
- A four-year efficacy and safety study of the long-acting parenteral testosterone undecanoateThe Aging Male, 2007
- Testosterone treatment comes of age: new options for hypogonadal menClinical Endocrinology, 2006
- Advances in male hormone substitution therapyExpert Opinion on Pharmacotherapy, 2005
- Nebido: a long-acting injectable testosterone for the treatment of male hypogonadismExpert Opinion on Pharmacotherapy, 2005
- Long-Term Pharmacokinetics of Transdermal Testosterone Gel in Hypogonadal MenThe Journal of Clinical Endocrinology & Metabolism, 2000
- Effect of Testosterone Treatment on Body Composition and Muscle Strength in Men Over 65 Years of AgeThe Journal of Clinical Endocrinology & Metabolism, 1999
- Testosterone Replacement With Transdermal Therapeutic SystemsJAMA, 1989
- ANDROGEN REPLACEMENT WITH ORAL TESTOSTERONE UNDECANOATE IN HYPOGONADAL MEN: A DOUBLE BLIND CONTROLLED STUDYClinical Endocrinology, 1981